Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 3 Breast Neoplasms 3 Ovarian Neoplasms 2 Tongue Neoplasms 1 Thymoma 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma, Endometrial Stromal 1 Sarcoma 1 Rhabdomyosarcoma 1 Recurrence 1 Rectal Neoplasms 1 Pleural Effusion, Malignant 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neoplasms 1 Melanoma 1 Liposarcoma 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Fibrosarcoma 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Dermatofibrosarcoma 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms, Male 1 Bone Neoplasms 1 Bone Diseases 1

Interventions

Gemcitabine 57 Paclitaxel 50 Cyclophosphamide 45 pembrolizumab 44 Carboplatin 41 Bevacizumab 38 Cisplatin 33 Docetaxel 31 Fluorouracil 30 Nivolumab 29 Capecitabine 29 Pemetrexed 24 Irinotecan 24 Oxaliplatin 23 Dexamethasone 23 Ipilimumab 22 Leucovorin 21 Radiotherapy 20 Sorafenib 19 Doxorubicin 19 Everolimus 18 Cetuximab 18 fludarabine 17 Albumin-Bound Paclitaxel 17 trametinib 15 Sunitinib 15 Rituximab 15 Erlotinib Hydrochloride 15 130-nm albumin-bound paclitaxel 15 Prednisone 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Neoplasms × saracatinib × Clear all

NCT00610714 2012-12-18

OVERT-1

AstraZeneca

Phase 2 Completed

211 enrolled 12 charts

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡